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Abstract
Background: Pleiotrophin (PTN) is a heparin-binding growth factor with significant role(s) in tumour growth and
angiogenesis. Although implication of endogenous PTN has been studied in several in vivo models of tumour
angiogenesis, its role in physiological angiogenesis has not been addressed. In the present work, we studied
expression and functional significance of endogenous PTN during angiogenesis in the chicken embryo
chorioallantoic membrane (CAM).
Methods: Using molecular, cellular and biochemical assays, we studied the expression pattern of PTN in CAM and
human endothelial cells and its possible interaction with nucleolin (NCL). CAM cells were transfected with a
pCDNA3.1 vector, empty (PC) or containing full length cDNA for PTN in antisense orientation (AS-PTN).
Angiogenesis was estimated by measuring total vessel length. In vitro, human endothelial cells migration was
studied by using a transwell assay, and down-regulation of NCL was performed by using a proper siRNA.
Results: Endogenous PTN mRNA and protein levels, as well as protein levels of its receptor protein tyrosine
phosphatase beta/zeta (RPTPb/ζ) were maximal at early stages, when CAM angiogenesis is active. Application of
AS-PTN onto CAM at days of active angiogenesis was not toxic to the tissue and led to dose-dependent decreased
expression of endogenous PTN, ERK1/2 activity and angiogenesis. Interestingly, endogenous PTN was also
immunolocalized at the endothelial cell nucleus, possibly through interaction with NCL, a protein that has a
significant role in the nuclear translocation of many proteins. Down-regulation of NCL by siRNA in human
endothelial cells significantly decreased nuclear PTN, verifying this hypothesis. Moreover, it led to abolishment of
PTN-induced endothelial cell migration, suggesting, for the first time, that PTN-NCL interaction has a functional
significance.
Conclusions: Expression of endogenous PTN correlates with and seems to be involved in angiogenesis of the
chicken embryo CAM. Our data suggest that NCL may have a role, increasing the number of growth factors whose
angiogenic/tumorigenic activities are mediated by NCL.
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Pleiotrophin (PTN) is an 18 kDa secreted protein with
high affinity for heparin. It is highly conserved among
species and together with midkine, belongs to a family
of heparin-binding growth factors with many similar
biological activities. It was initially purified from bovine
uterus and neonatal rat brain, and its expression has
been detected increased in several developing tissues,
such as the nervous system, deciduas basalis and mam-
mary gland, bone and cartilage, liver, kidney, lung, the
epithelial ridge of the cochlea, retinas and corneas.
Although its functional role has not been always eluci-
dated, it displays important functions in growth and dif-
ferentiation processes, such as neurite outgrowth and
synaptic plasticity, fertility, development and regenera-
tion of liver, auditory function, would healing and adi-
pogenesis. The best characterized functions of PTN up
to date are those concerning its role(s) in the nervous
system, as well as its involvement in tumour growth.
The latter was initially supported by the fact that PTN
has been detected in various human carcinomas, such as
meningiomas, neuroblastomas, diffuse astrocytomas,
glioblastomas, melanomas, multiple myeloma, prostate
cancer, cancer of the pancreas, breast cancer, small cell
lung cancer, malignant tumor of the testis, solid paedia-
tric tumours, uterine cervical cancer and leiomyomas,
while it has been also detected in serum of patients with
breast, colon, pancreas, lung cancers and multiple mye-
loma. It is also constitutively expressed in cell lines
derived from different types of tumours and is involved
in tumour growth and metastasis in several experimen-
tal models. When PTN expression is up-regulated in
normal cells the latter acquire a more malignant pheno-
type, while down-regulation of PTN expression
decreases tumour cell proliferation and invasion in vitro,
as well as tumour growth, metastases and angiogenesis
in vivo, indicating a possible implication of PTN in the
blood vessel network formation of solid tumours
reviewed in [1,2]. Besides a role in tumour angiogenesis,
we have previously shown that exogenously adminis-
tered PTN induces angiogenesis in several in vitro mod-
els of angiogenesis [3-5] and in vivo,i nt h ec h i c k e n
embryo chorioallantoic membrane (CAM) [3]. Although
the role of PTN has been studied in several in vivo
models of tumour growth, there are no in vivo studies
on the role of endogenous PTN in physiological
angiogenesis.
PTN acts through several cell surface receptors, such
as N-syndecan, anaplastic lymphoma kinase (ALK),
receptor protein tyrosine phosphatase beta/zeta
(RPTPb/ζ)a n daνb3 integrin. Although ALK has been
implicated in actions of PTN related to tumour growth,
the best characterized receptor up to date, implicated in
the tumour promoting activities of PTN is RPTPb/ζ
reviewed in [1,2]. We have previously shown that
RPTPb/ζ is required for the stimulatory effects of PTN
on human endothelial cell migration and tube formation
on matrigel in vitro [4] but only when aνb3 integrin is
also expressed [5]. Expression of integrin aνb3 is low in
quiescent and high in angiogenic endothelial cells [6]; in
CAM endothelial cells, aνb3 is expressed during the
stages of new blood vessel formation [7]. Nucleolin
(NCL) is also considered a low affinity receptor for PTN
[8], although it has not been connected to any of PTN’s
biological activities. NCL is a multifunctional nucleolar
protein that among other functions, acts as a shuttling
protein between cytoplasm and nucleus [9]. NCL has
been shown to import midkine into the nuclear fraction
[10]. Based on the similarity of the two molecules, it has
been hypothesized that NCL may also import PTN into
the nuclear fraction [10], although this has never been
shown up to date.
In the present study, we investigated the expression
and the possible role of endogenous PTN and its recep-
tors in the in vivo angiogenesis model of the chicken
embryo CAM. Expression of endogenous PTN and its
receptor RPTPb/ζ correlates with angiogenesis of the
c h i c k e ne m b r y oC A M .P T Ns e e m st ob ei n v o l v e di n
CAM angiogenesis and NCL may have a role in the
angiogenic functions of PTN both in vivo and in vitro.
Methods
Antibodies, oligonucleotides, and reagents
Cell culture reagents were from BiochromKG (Seromed,
Germany). Human recombinant PTN was from Pepro-
tech Inc (Rocky Hill, NJ, USA) or was prepared as pre-
viously described [3]. Monoclonal antibody against NCL,
affinity purified rabbit polyclonal antibody against PTN
(used for immunoprecipitations and immunohistochem-
istry of CAM paraffin sections) and goat polyclonal anti-
body against RPTPb/ζ were from Santa Cruz
Biotechnology Inc (Santa Cruz, CA, USA). Monoclonal
antibody against PTN (used only in human cells) was
from Abnova (Taipei City, Taiwan), goat polyclonal anti-
body against PTN was from R&D Systems (Minneapolis,
MN, USA), antibody against phospho-ERK1/2 on
Thr
202-Tyr
204 was from Cell Signalling (Danvers, MA,
USA), antibody against ERK1/2 was from Upstate Bio-
technology (Lake Placid, NY, USA), antibody against
Prox-1 was from Axxora (San Diego, CA, USA), antibo-
dies against b-actin and aνb3 were from Chemicon
(Temecula, CA, USA) and monoclonal antibody against
RPTPb/ζ was from BD Transduction Laboratories (San
Diego, CA, USA). Protein A and G agarose beads were
purchased from Merck (Whitehouse Station, NJ, USA).
DNA oligonucleotide primers for chicken PTN and
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were obtained from VBC Biotech Services (Vienna, Aus-
tria). Double-stranded negative control siRNA was
obtained from Ambion (Austin, TX, USA) and the
transfection reagents Jet-PEI and JetSI-ENDO were from
Polyplus Transfection (Illkirch, France). Alexa secondary
antibodies were from Molecular Probes (Carlsbad, CA,
USA). Rabbit polyclonal antibody against NCL (used
only in immunofluorescent studies), human IgG and all
secondary horseradish peroxidase-conjugated antibodies
were purchased from Sigma (St. Louis, MO, USA).
Draq5 was from Biostatus Limited (Leicestershire, Uni-
ted Kingdom). The 9-fluorenylmethoxycarbonyl (Fmoc)-
protected amino acids, Wang resin and peptide reagents
were purchased from CBL (Patras, Greece), Bachem
(Bubendorf, Switzerland) and Novabiochem (Läufelfin-
gen, Switzerland). All other reagents, unless mentioned
below, were purchased from Sigma or Applichem
(Darmstadt, Germany).
CAM assay
The in vivo chicken embryo CAM angiogenesis assay
was used, as previously described [3]. Leghorn fertilized
eggs (Pindos, Ioannina, Greece) were incubated for 4
days at 37°C, when a window was opened on the egg
shell, exposing the chorioallantoic membrane. The win-
dow was covered with tape and the eggs were returned
to the incubator. Different amounts of pCDNA3.1 alone
or pCDNA3.1 carrying full length cDNA for PTN in
antisense orientation (AS-PTN) [11], were diluted in a
final volume of 50 μl of phosphate buffered saline pH
7.4 (PBS) containing jet-PEI (N/P = 5 ratio) and were
applied at the 9
th day of embryo development on an
a r e ao f1c m
2 of the CAM, restricted by a plastic ring.
Forty eight hours after treatment and subsequent incu-
bation at 37°C, CAMs were fixed in situ, excised from
the eggs, placed on slides and left to air-dry. Pictures
were taken through a stereoscope equipped with a digi-
tal camera and the total length of the vessels was mea-
sured, as previously described [3]. Assays were carried
out three times and each experiment contained 10-20
eggs per data point.
For the biochemical studies, plasmids were applied on
the CAM as described above, and after 24 h of incuba-
tion at 37°C, the CAMs were excised from the eggs, cut
in pieces, washed three times in PBS and stored at -80°
C until used [12]. Assays were carried out three times
and each experiment contained 5-10 eggs per data
point.
Haematoxylin-eosin staining and immunohistochemistry
of CAM paraffin sections
Tissues from various developmental stages were excised
from the eggs, washed in PBS, fixed in saline-buffered
formalin and embedded in paraffin. Sections were cut at
5 μm thickness and placed on positively charged glass
slides. After rehydration, the tissue sections were stained
with standard haematoxylin-eosin staining or processed
for immunohistochemistry. In the latter case, endogen-
ous peroxidase was blocked with 3% H2O2 for 30 min in
a dark chamber at room temperature. Tissue sections
were then incubated with blocking agent (Kwik Kits,
Immunon Immunohistochemicals, Lipshaw, USA) for 15
min at room temperature to prevent non specific bind-
ing of antibodies, followed by incubation with 5 μg/ml
of affinity purified rabbit anti-PTN IgG in Tris-buffered
saline (TBS), pH 7.4, with 0.05% Tween (TBS-T) con-
taining 2% bovine serum albumin (BSA) for 1 h at 37°C.
After 3 washes of 2 min each in TBS-T, a second 30
min incubation at room temperature, using a horserad-
ish peroxidase conjugated goat anti-rabbit IgG was per-
formed at a dilution of 1:5,000 in TBS-T containing 2%
BSA. After three washes of 2 min each in TBS, detection
of PTN was performed by DAB staining. Sections were
mounted in mounting fluid, viewed in a Zeiss micro-
scope and photographed using a digital camera [12].
Cell culture
Human umbilical vein endothelial cells (HUVEC) used
in the present study were isolated from human umbilical
cords and cultured as previously described [3]. HUVEC
were grown as monolayers in medium M199 that was
supplemented with 15% fetal bovine serum (FBS), 150
μg/ml endothelial cell growth supplement, 5 U/ml
heparin sodium, 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 50 μg/ml gentamycin and 2.5 μg/ml amphoteri-
cin B and used at passages 2-3. U87MG cells (ATCC)
were grown routinely in Dulbecco’s modified Eagle med-
ium (DMEM)/Ham’s F12 medium supplemented with
10% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin,
50 μg/ml gentamycin, and 2.5 μg/ml amphotericin B.
Cultures were maintained at 37°C, 5% CO2, and 100%
humidity. When cells reached 70-80% confluence, they
were lysed for immunoprecipitation experiments or
fixed for immunofluorescent studies.
Migration assay
Migration assays were performed as described previously
[3,5] in 24-well microchemotaxis chambers (Corning,
Inc., Lowell, MA, USA) using uncoated polycarbonate
membranes with 8-μm pores. Serum-starved cells were
harvested and resuspended at a concentration of 10
5
cells/0.1 ml in serum-free medium containing 0.25%
BSA. The bottom chamber was filled with 0.6 ml of
serum-free medium containing 0.25% BSA and the
tested substances. The upper chamber was loaded with
0.1 ml of serum-free medium containing 10
5 cells and
incubated for 4 h at 37°C. After completion of the
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toluidine blue solution. The cells that migrated through
the filter were quantified by counting the entire area of
each filter, using a grid and an Optech microscope at
X20 (Optech Microscope Services Ltd., Thame, UK).
Western blot analysis
CAMs from various developmental stages or after treat-
ment with the plasmids were homogenized using a
glass-glass homogenizer in 20 mM Hepes, pH 7.4, con-
taining 2 M NaCl supplemented with 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 5 mM EDTA and 1 μg/
ml aprotinin. The homogenate was centrifuged at
10,000 x g for 20 min at 4°C. Equal amounts (100 μg) of
total protein from CAM lysates or the immunoprecipi-
tated samples, as described below, were analysed by
SDS-PAGE and transferred to Immobilon P membranes.
Blocking was performed by incubating the membranes
with TBS-T containing 3% BSA in the case of PTN,
RPTPb/ζ, PROX-1, phosphorylated ERK1/2 (pERK1/2)
and total ERK1/2 (tERK1/2) and 5% non-fat dry milk in
the case of NCL and actin. Membranes were incubated
with primary antibodies for 16 h at 4°C under continu-
ous agitation, washed 3 times with TBS-T, and incu-
bated with secondary antibodies for 1 h at room
temperature. Membranes were finally washed and detec-
tion of immunoreactive bands was performed using the
ECL detection kit (Pierce), according to the manufac-
turer’s instructions. Blots for PTN, NCL and PROX-1,
where appropriate, were stripped and subjected to sub-
sequent Western blotting for actin. Blots for pERK1/2
were stripped and subjected to subsequent Western
blotting for total ERK1/2. The protein amounts that cor-
responded to each immunoreactive band were quantified
from digital images of gels, using the ImagePC image
analysis software (Scion Corporation, Frederick, MD)
[5,12].
Immunoprecipitation assays
CAMs or cells were homogenised or lysed, respectively,
in PBS containing 1% Triton X-100, 0.1% SDS, 20 nM
sodium orthovanadate, 1 μg/ml aprotinin, 1 mM phenyl-
methylsulfonyl fluoride and 5 mM EDTA. Homogenates
or lysates were centrifuged at 20,000 g for 30 min at 4°
C. Three mg of total protein were transferred to new
eppendorf tubes and incubated with primary antibodies
for 16 h at 4°C under continuous agitation. Protein A-
and protein G-agarose beads were added and samples
were further incubated for 2 h at 4°C. Beads and bound
proteins were collected by centrifugation and washed
twice with ice-cold PBS [5]. The pellet was resuspended
in 50 μl SDS loading buffer, heated to 95-100°C for 5
min, centrifuged and analyzed by Western blot analysis
as described above.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
for PTN
Total RNA was extracted from CAMs of various devel-
opmental stages using the Nucleospin RNA II kit
(Macherey-Nagel, Germany), according to the manufac-
turer’s instructions. Primers used for the detection of
PTN mRNA were designed according to the chicken
sequence (Accession number BI394859) and were: 5’-
AGA GAA ACC AGA GAA AAA GG-3’ (sense) and 5’-
CAG TCA GCA TTA TGA AGA GC-3’ (antisense),
yielding a product of 288 bp. The reporter gene was the
chicken glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and the primers used were: 5’-ACG GAT
TTG GCC GTA TTG GC-3’ (sense) and 5’-GCA GGA
TGC GAA ACT GAG CG-3’ (antisense) [13]. The RT-
PCR reactions for PTN and GAPDH were performed in
a single step, using the Access RT-PCR system (Pro-
mega) under the following conditions: The reverse tran-
scriptase reaction was performed by AMV-RT for 1 h at
48°C. After an initial denaturation step for 2 min at 94°
C, 30 cycles of amplification (94°C for 1 min, 57°C for
40 sec and 68°C for 1.5 min for GAPDH and 94°C for 1
min, 55°C for 40 sec and 68°C for 1.5 min for PTN)
were performed and ended with a final DNA synthesis
step at 68°C for 7 min. In all cases, PCRs were not in
the saturating phase (data not shown). DNA contamina-
tion was excluded by performing PCR reactions in the
absence of the reverse transcription step. The RT-PCR
products were subjected to electrophoresis on 2% agar-
ose gels containing 0.5 μg/ml ethidium bromide and
photographed using a digital camera. The bands were
quantified (area and intensity) using Image PC image
analysis software and the ratios PTN/GAPDH of elec-
trophoretic band values represent the relative expression
of ptn gene at different days of embryo development.
RNA interference
The short interfering RNA against NCL was sense: 5’-
GGAAGGUCAGCAGUCUUCCAUGAGA-3’ and anti-
sense: 5’-UCUCAUGGAAGACUGCUGACCUUCC-3’
[14]. HUVEC were grown to a confluence of 50% in
medium without antibiotics. Transfection was performed
in serum-containing medium for 4 h using annealed
RNA for NCL at the concentration of 50 nM and jetSI-
ENDO as transfection reagent. Cells were incubated for
another 24 h in serum-containing medium and lysed in
order to evaluate transfection efficiency by Western blot
analysis, or fixed for immunofluorescent studies. Dou-
ble-stranded negative control siRNA from Ambion (cat-
alogue # AM4635) was used in all assays.
Immunofluorescence
For immunofluorescent studies, cells were fixed by 4%
paraformaldehyde for 10 min. After being washed 3
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taining 3% BSA and 10% FBS for 1 h at room tempera-
ture. The cells were stained with primary antibodies
against NCL (1:1,000) and PTN (1:500). Nuclei were
stained with Draq5 (final concentration 3.3 μM). Fluor-
escent secondary antibodies were used at the concentra-
tion of 1:500, and the cells were mounted with Mowiol
4-88 (Calbiochem, San Diego, CA, USA) and visualized
at 21°C with Leica SP5 (X63 objective with a numerical
aperture of 1.4; Leica Microsystems, Wetzlar, Germany)
confocal microscope.
Subcellular fractionation
Subcellular fractions of U87MG cells comprising cytoso-
lic, nuclear and cell membrane extracts were prepared
as follows [15]: Cell monolayers in 100-mm plates were
washed extensively with PBS before being scraped and
pelleted. Washed cells (30 × 10
9) were then disrupted in
a hypotonic solution (10 mM Hepes, pH 6.9, 10 mM
KCl, 2 mM MgCl2, 1000 units/ml aprotinin, 0.1 mM
PMSF) on ice. Nuclei were pelleted at 400 g for 5 min
and washed twice in PBS beforee x t r a c t i o ni nt h el y s i s
buffer (10 mM Tris-HCl, pH 7.6, 400 mM NaCl, 1 mM
EDTA, 1000 units/ml aprotinin, 0.1 mM PMSF, and 1%
Triton X-100). The lysate was centrifuged at 12,000 g
for 10 min and the supernatant was referred to as the
nuclear fraction. The supernatant obtained after pellet-
ing intact nuclei was further centrifuged at 14,000 g for
30 min and the supernatant corresponding to the cyto-
solic fraction was recovered, while the pellet was resus-
pended in lysis buffer containing 150 mM instead of
400 mM NaCl. This latter suspension was centrifuged at
14,000 g for 30 min to separate the cytoskeletal (the pel-
let) and membrane (supernatant) fractions. Equivalent
total protein amounts of each fraction corresponding to
nuclei, cytosol, and membrane were immunoprecipitated
for PTN and then analyzed by Western blot analysis for
PTN or NCL.
Synthesis of the 5(KPR)TASP peptide
5(KPR) TASP peptide, a potent and selective ligand of
cell surface nucleolin, was synthesized by the solid
phase method using protected Fmoc amino acids and
Wang resin as the solid support [16]. In summary,
Fmoc-protected amino acids were used with the t-Butyl
group as side-chain protecting group for Glu, tert-butu-
loxycarbony group (t-Boc) and/or 4-methoxytrityl group
for Lys, t-Boc group for Trp, trityl group for Cys and
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
group for Arg. Stepwise synthesis of the TASP core pep-
tide was achieved using diisopropylcarbodiimide/1-
hydroxybenzotriazole as coupling reagents. The KPR tri-
peptide was step by step synthesized on ε-aminogroup
of the lysine residues in positions 1,3,6,8 as well on the
aminoterminal of the TASP core using HATU/DIPEA
in dimethylformamide as coupling agents. After comple-
tion of the synthesis, the resin was treated with a tri-
fluoroacetic acid solution (TFA/1,2-ethanedithiol/
triethylsilane/water/anisole, 95/1/1/1/2 v/v/v/v/v) in the
presence of scavengers to liberate the fully deprotected
crude peptide. The released peptide was precipitated
upon solvent concentration and addition of cold ether
and the final product was purified by gel filtration chro-
matography on Sephadex G-15 using 20% acetic acid as
the eluent. Final purification was achieved by preparative
high performance liquid chromatography. The final 5
(KPR)TASP peptide was checked for its purity by analy-
tical HPLC on a Lichrosorb RP18 column (C18 solid
phase, 7 μm particle size, 250 mm × 8 mm) applying a
linear gradient 10%-70% acetonitrile (0.1% TFA) for 35
minutes, and 70%- 100% acetonitrile (0.1% TFA) for 5
minutes (flow rate 1.5 mL/min, UV detection at 220 nm
and 254 nm). The final verification of the peptide
sequence was achieved by Electron Spray Ionization-
Mass Spectrometry.
Statistical analysis
The significance of variability between the results from
various groups was determined by one way ANOVA.
Each experiment included triplicate measurements for
each condition tested, unless otherwise indicated. All
results are expressed as mean ± S.E.M. from at least
three independent experiments.
Results
PTN is expressed by chicken embryo CAM cells and
interacts with RPTPb/ζ
Initially, we investigated whether PTN is physiologically
expressed by CAM cells. In order to do this, we per-
formed Western blot and RT-PCR analyses to detect
PTN at several stages of embryo development. Equal
amounts of total CAM proteins from tissues of different
developmental stages were analyzed by 17.5% SDS-
PAGE. Western blot analysis showed that PTN protein
was present in the chicken embryo CAM at all embryo-
nic developmental stages, its amounts were maximal at
day 6 of embryo development and declined progressively
until day 18 (Figure 1A). Using semi-quantitative RT-
PCR, it was found that PTN mRNA levels were also
maximal at day 6 of embryo development, remained at
high levels till day 12 and were decreased at later devel-
opmental stages (Figure 1B). RPTPb/ζ protein was also
present in the chicken embryo CAM at all embryonic
developmental stages, its amounts were maximal at days
6-12 of embryo development and declined progressively
until day 18 (Figure 1C). We could not detect RPTPb/ζ
at the mRNA level since the chicken gene is not known
a n dt h eh u m a np r i m e r st e s t e dd i dn o tf o r ma n y
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Page 5 of 13Figure 1 Detection of endogenous PTN and RPTPb/ζ in the chicken embryo CAM. A. Equal amounts of protein extracts of chicken embryo
CAM from different developmental stages were analyzed by SDS-PAGE, followed by Western blot analysis for PTN and actin. The protein
amounts were quantified by densitometric analysis of the corresponding bands and the ratio PTN/actin was calculated for each lane. B. Products
of RT-PCR reactions for chicken PTN and GAPDH from mRNA of chicken embryo CAM from different developmental stages. The mRNA amounts
were quantified by densitometric analysis of the corresponding bands and the ratio PTN/GAPDH was calculated in each lane. Results in both A
and B are expressed as mean ± S.E.M. of the % change of the PTN relative amounts compared to day 6. C. Three mg of total protein from
chicken embryo CAM extracts from different developmental stages were subjected to immunoprecipitation for RPTPb/ζ. Precipitated proteins
were analyzed by SDS-PAGE, followed by Western blot for the presence of RPTPb/ζ. D. Three mg of total protein from chicken embryo CAM
extracts from different developmental stages were subjected to immunoprecipitation for RPTPb/ζ. Precipitated proteins were analyzed by SDS-
PAGE, followed by Western blot analysis for the presence of PTN. The protein amounts in C and D were quantified by densitometric analysis of
the corresponding bands and results are expressed as mean ± S.E.M. of the % change compared to day 6. Asterisks in all cases denote a
statistically significant difference from day 6. **P < 0.01, ***P < 0.001.
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from CAM protein extracts and this interaction was also
maximal at days 6-12 of embryo development (Figure
1D). Interestingly, integrin aνb3 also interacts with
RPTPb/ζ when there is active angiogenesis, while this
interaction is decreased when angiogenesis of the tissue
has stopped (Additional file 1).
Decrease of endogenous PTN expression results in
decreased angiogenesis in the chicken embryo CAM
Since PTN expression correlates with blood vessel for-
mation in the CAM, we studied if down-regulation of
its expression would decrease angiogenesis of the tissue.
AS-PTN or empty pCDNA3.1 vectors were applied on
the CAM at day 9 of embryo development, as described
in Methods. As shown in Figure 2A, application of AS-
PTN onto CAM led to decreased amounts of endogen-
ous PTN in a dose-dependent manner, suggesting that
expression of PTN was significantly affected by this
treatment, without being toxic to the tissue as evidenced
by haematoxylin-eosin staining of CAM paraffin sections
(Figure 2B). Decreased expression of endogenous PTN
by CAM cells correlated with a dose-dependent decrease
in tissue angiogenesis (Figure 2C) and ERK1/2 activity
(Figure 2D). In contrast, it did not affect the expression
of the lymphatic endothelial cells’ marker PROX-1 (Fig-
ure 2E). Similarly to CAM angiogenesis, PROX-1
expression is increased till day 12 of embryo develop-
ment and significantly decreased at later developmental
stages (Additional file 2).
PTN directly interacts with NCL in CAM and human
endothelial cells
By using immunohistochemistry in CAM paraffin sec-
tions we found that endothelial cells were positive for
PTN; it is noteworthy that PTN immunoreactivity was
also detected in the nucleus of CAM endothelial cells
(Figure 3A). Based on this observation, we studied
whether PTN interacts with NCL, a protein that partici-
pates in the transport between cytoplasm and nucleus of
several molecules [17-19], among which midkine [10].
By immunoprecipitating CAM proteins against NCL
and analyzing immunoprecipitates for the presence of
PTN, we found that PTN co-immunoprecipitated with
NCL (Figure 3B). We verified PTN nuclear localization,
as well as PTN-NCL interaction in HUVEC, by a combi-
nation of immunoprecipitation, Western blot and
immunofluorescent analyses. PTN was co-immunopreci-
pitated with NCL in HUVEC lysates (Figure 3C) and co-
localized with NCL in the nucleus, cytoplasm and cell
membrane of HUVEC (Figure 3D). By performing sub-
cellular fractionation assay, similar pattern of co-locali-
zation of PTN with NCL was also observed in U87MG
cancer cells (Additional file 3), suggesting that the
interaction between PTN and NCL is common to sev-
eral types of cells. In order to investigate whether NCL
is playing a role in the nuclear localization of PTN, we
down-regulated NCL expression in HUVEC by siRNA
(Figure 3E), and examined the subcellular localization of
PTN by immunofluorescence microscopy. As shown in
Figure 3F, when NCL expression was down-regulated,
PTN localization in the nucleus was significantly
decreased.
Down-regulation of NCL abolishes PTN-induced migration
of human endothelial cells
In order to determine whether NCL is involved in PTN-
induced endothelial cell migration, we studied PTN-
induced migration of HUVEC after down-regulation of
NCL expression by siRNA. As shown in Figure 4A,
down-regulation of NCL expression resulted in com-
plete inhibition of PTN-induced endothelial cell migra-
tion. We furthermore studied PTN-induced migration
of HUVEC in the presence of the 5(KPR)TASP pseudo-
peptide that is known to bind the C-terminal RGG
domain of cell-surface expressed NCL and block its
function [16]. 5(KPR)TASP pseudopeptide completely
abolished PTN-induced HUVEC migration (Figure 4B),
further suggesting involvement of NCL in the angio-
genic functions of PTN. The concentration of PTN used
in all in vitro assays was 100 ng/ml, which causes a
maximal effect on endothelial cell migration [4].
Discussion
PTN is expressed in a variety of primary human
tumours and has been correlated with enhanced tumour
growth and vascular density reviewed in [2]. We have
previously shown that exogenously administered human
recombinant PTN is angiogenic in several in vitro mod-
els and in the chicken embryo CAM model in vivo [3].
I nt h ep r e s e n ts t u d yw es h o wt h a te n d o g e n o u sP T Ni s
playing a significant role in the vascularisation of the
chicken embryo CAM. This is supported by our findings
that: a) Expression of endogenous PTN is maximal at
early developmental stages, when there is active
endothelial cell proliferation, migration and angiogen-
esis, and is decreased later, when there is no endothelial
cell proliferation and migration [20], and b) decreased
expression of endogenous PTN resulted in decreased
angiogenesis of the tissue, directly linking PTN expres-
sion with new blood vessel formation. In favour of a sti-
mulatory effect of PTN on in vivo angiogenesis are also
our additional data showing that exogenously added
PTN onto the chicken embryo CAM increases the
mRNA levels of vascular endothelial growth factor
(VEGF) isoforms 165 and 190, as well as activates metal-
loproteinase 2 (Additional file 4). These data are in line
with a recent work showing that PTN promotes VEGF
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Page 7 of 13Figure 2 Decreased expression of endogenous PTN following transfection of CAM cells with pCDNA3.1 carrying AS-PTN results in
decreased angiogenesis. A. Equal amounts of protein extracts of chicken embryo CAM 24 h after application of pCDNA3.1 alone (PC) or
carrying AS-PTN (AS) were analyzed by SDS-PAGE, followed by Western blot analysis for PTN and actin. B. Haematoxylin & eosin staining of CAM
paraffin sections 24 h after application of 1 μg of pCDNA3.1 alone (PC) or carrying AS-PTN (AS). Untreated CAM paraffin sections at the same
developmental stage were used as control. C. Different amounts of pCDNA3.1 alone or carrying AS-PTN were applied on the CAM and 48 h later
the number of vessels was estimated using image analysis software. Results are expressed as mean ± S.E.M. of the % change of the total vessel
length in treated with pCDNA3.1 carrying AS-PTN (AS) compared with the tissue treated with pCDNA3.1 vector alone (PC) at the same quantity
(control). Asterisks denote a statistically significant difference (unpaired t-test) from the control. ***P < 0.001. The pictures are representative,
showing the vessel network of the chicken embryo CAM after treatment with 1 μg pCDNA3.1 alone (PC) or carrying AS-PTN (AS). D.
Representative pictures of Western blot analyses from three independent experiments for phosphorylated ERK1/2 (pERK1/2) and total ERK1/2
(tERK1/2) in protein extracts of chicken embryo CAM 24 h after application of pCDNA3.1 alone (PC) or carrying AS-PTN (AS). Phospho- and total
protein amounts were quantified by densitometric analysis of the corresponding band in each lane, and the ratio pERK1/2/tERK1/2 was
calculated in each lane. Results are mean ± S.E.M. of the % change of ERK1/2 phosphorylation in treated with pCDNA3.1 carrying AS-PTN (AS)
compared with the tissue treated with pCDNA3.1 vector alone (PC) at the same quantity (control). Asterisks denote a statistically significant
difference (unpaired t-test) from the control. *P < 0.05. E. Representative pictures of Western blot analyses from three independent experiments
for PROX-1 and actin in protein extracts of chicken embryo CAM 24 h after application of pCDNA3.1 alone (PC) or carrying AS-PTN (AS).
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Figure 3 NCL is playing a role in the nuclear translocation of PTN. A. Cellular localization of PTN protein in paraffin sections of chicken
embryo CAM at day 9 of embryo development. Arrows on the left picture indicate an intense PTN immunoreactivity in the nucleus of
endothelial cells (40× magnification). The picture on the right shows a CAM paraffin section treated only with the secondary antibody (20×
magnification). B. Equal amounts of protein extracts of chicken embryo CAM from days 6 (d6) and 9 (d9) of embryo development were
subjected to immunoprecipitation for IgG or NCL. The precipitated proteins were analyzed by Western blot for the presence of PTN. C. Equal
amounts of protein extracts of HUVEC were subjected to immunoprecipitation for IgG, PTN or NCL. The precipitated proteins were analyzed by
SDS-PAGE, followed by Western blot analysis for the presence of NCL or PTN respectively. D. Representative immunofluorescent images of
HUVEC stained for PTN (red), NCL (green) and nucleus (blue). E. HUVEC lysates or fixed cells after treatment for 24 h with siRNA for NCL were
analyzed for the presence of NCL, by Western blot or immunofluorescence respectively. F. Representative immunofluorescent images of HUVEC
stained for PTN (green) and nucleus (blue) after down-regulation of NCL expression by siRNA. siNEG, cells transfected with a negative control
siRNA; siNCL, cells transfected with siRNA for NCL.
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Page 9 of 13expression and cooperates with VEGF in promoting col-
orectal cancer angiogenesis [21]. Interestingly, although
PTN seems to affect the number of angiogenic blood
vessels, it did not affect lymphatic endothelial cells’ mar-
ker PROX-1 expression, suggesting that PTN does not
affect lymphatic vessel density, in line with data on col-
orectal cancer showing that lymphatic microvessel den-
sity does not correlate with PTN expression [21].
The mechanisms involved in the angiogenic action of
PTN in vivo are not completely clear. We have
previously shown that RPTPb/ζ is responsible for PTN-
induced endothelial cell migration [4]. In the chicken
embryo CAM, we have detected RPTPb/ζ at the protein
level and found that it interacts with PTN and its
expression is maximal at the early developmental stages,
similarly to the expression of PTN. Besides RPTRPb/ζ,
aνb3 integrin seems to be critical for the stimulatory
effect of PTN on endothelial cell migration, by forming
a functional complex with RPTPb/ζ on the cell surface
[5]. Integrin aνb3 directly interacts with PTN and
RPTPb/ζ in the chicken embryo CAM [5], is activated
on CAM endothelial cells only when there is active
angiogenesis [7], and interacts with RPTPb/ζ when there
is active angiogenesis, while this interaction is decreased
when angiogenesis of the tissue has stopped. However,
besides a direct effect on endothelial cells, it is also pos-
sible that PTN has an indirect effect, potentiating the
angiogenic effect of other growth factors. For example,
it has been previously shown that PTN induces prolif-
eration of human peripheral blood mononuclear cells
[22] and increases the mRNA expression of the VEGF
receptor Flt-1 in endothelial cell cultures [23]. Flt-1 is
expressed by monocytes and its expression is increased
after monocyte activation [24]. In the same line, recent
findings show that PTN induces transformation of
monocytes into functional endothelial cells, thus sup-
porting angiogenesis [25,26]. It may be possible that at
least part of the angiogenic effect of PTN in the chicken
embryo CAM is due to activation of CAM blood cells.
It is well known that PTN activates ERK1/2 in several
types of cells [27-29], among which endothelial cells [4],
and this pathway has been linked to stimulation of
endothelial cell proliferation [28] and migration [4]. In
the present study we show that decreased expression of
endogenous PTN leads to decreased ERK1/2 activity,
which correlates with the effect on tissue angiogenesis,
suggesting that PTN-induced ERK1/2 activation may be
important for the stimulation of PTN’s angiogenic activ-
ities in vivo, similarly to what has been known from in
vitro studies [4,28].
It is noteworthy that in the CAM, endogenous PTN is
also localized in the nucleus of endothelial cells. Similar
observation has been obtained using HUVEC and
U87MG cells (present study), as well as other types of
cells that express endogenous PTN, such as neonatal
cardiomyocytes [30]. Over the past years, evidence has
accumulated that several growth factors related to
angiogenesis and tumour growth, as well as their recep-
tors, are found in the cell nucleus. Although this nuclear
distribution might be related to the transcriptional acti-
vation of genes involved in the angiogenic cascade, at
the moment the precise function of this process is com-
pletely unknown (reviewed in [31]). Nuclear transloca-
tion of PTN has been previously discussed, based on the
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Figure 4 NCL plays a role in PTN-induced endothelial cell
migration. A. Down-regulation of NCL expression by siRNA
completely abolished PTN-induced HUVEC migration. B. Blockage of
cell surface NCL by its ligand 5(KPR)TASP (TASP, 1 μM) completely
abolished PTN-induced HUVEC migration. Results are expressed as
percent of the values obtained in untreated cells (control). Data are
the mean ± S.E.M. of three independent experiments. Asterisks
denote a statistically significant difference from control. *P < 0.05,
**P < 0.01. NT, non transfected cells; siNEG, cells transfected with a
negative control siRNA; siNCL, cells transfected with siRNA for NCL.
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Page 10 of 13observations that its primary structure contains three
potential nuclear targeting sequences [32], it was found
to bind to NCL [33], and NCL was found to participate
in midkine nuclear translocation [10,33]. Although inter-
action of PTN with NCL has been previously mentioned
[8], it is the first time that it is clearly shown that NCL
participates in PTN nuclear translocation. At the
moment, the functional significance of the nuclear loca-
lization of PTN is completely unknown. One possibility
for the role of nuclear PTN could be an involvement in
cell cycle progression. It has been previously shown that
interruption of PTN expression induces tetraploidy and
aneuploidy in U87MG cells and may contribute to the
reversal of their highly malignant phenotype [34].
Another possibility might be a role in apoptosis. There
are many studies supporting an anti-apoptotic effect of
PTN [35-38], in line with studies supporting an anti-
apoptotic effect of NCL [39-41]. However, it has not
been clear whether this anti-apoptotic effect is due to
the nuclear localization of PTN and further studies are
required to elucidate this point. Finally, it has been
recently shown that NCL interacts with the G-rich
strands in the pPu/pPy tract of the VEGF promoter and
acts as transcriptional activator of the VEGF gene [42].
PTN also promotes VEGF expression [21] and the pos-
sibility that PTN and NCL co-operate in regulating
expression of several molecules is interesting and is
further studied.
Besides translocation to the nucleus, NCL seems to
also participate in PTN-induced endothelial cell migra-
tion. This seems to be mediated mainly by the cell sur-
face NCL and to the best of our knowledge, this is the
first study to show direct interaction between the two
molecules on the cell surface and implication of NCL
in angiogenic functions of PTN. Extranuclear distribu-
tion of NCL has been observed in both endothelial
[17] and cancer [19,43,44] cells and seems to partici-
pate in functions that lead to angiogenesis and tumour
growth, through yet unknown mechanisms. A specific
antagonist that binds the C-terminal tail of NCL, simi-
larly to the 5(KPR)TASP peptide we used in the pre-
sent study, decreased blood vessel branching in the
chicken embryo CAM [43]. This peptide forms a stable
complex with cell surface-expressed NCL [43], suggest-
ing that the latter plays a role in CAM angiogenesis
and participates in PTN-induced endothelial cell
migration. A number of recent studies suggest that
several molecules that affect angiogenesis and tumour
growth act through cell surface NCL, such as hepato-
cyte growth factor [45], VEGF [46], endostatin [47,48]
and tumour necrosis factor-alpha inducing protein
[49], favouring the notion that targeting of cell surface
NCL may prove to be an effective anticancer therapy
[50,51].
In summary, our data suggest that expression of endo-
genous PTN and its receptor RPTPb/ζ in the CAM is
related to new blood vessel formation. PTN seems to be
involved in angiogenesis of the tissue, possibly through
interaction with its cell surface receptors and ERK1/2
activation. NCL interacts with PTN on the cell surface,
is involved in the nuclear translocation of PTN and may
have a role in the angiogenic functions of PTN both in
vivo and in vitro.
Additional material
Additional file 1: Co-immunoprecipitation of RPTPb/ζ with aνb3 in
the chicken embryo CAM during embryo development. Three mg of
total protein from chicken embryo CAM extracts from different
developmental stages were subjected to immunoprecipitation for aνb3.
Precipitated proteins were analyzed by SDS-PAGE, followed by Western
blot analysis for the presence of RPTPb/ζ. Both transmembrane splice
variants of RPTPb/ζ (Garwood et al., J Biol Chem 2003, 278:24164-24173)
have been detected.
Additional file 2: Detection of PROX-1 in the chicken embryo CAM
during embryo development. Equal amounts of protein extracts of
chicken embryo CAM from different developmental stages were analyzed
by SDS-PAGE, followed by Western blot analysis for PROX-1 and actin.
Additional file 3: Interaction of PTN with NCL in human glioma
U87MG cells. A. Equal total protein amounts of subcellular fractions of
U87MG cells were immunoprecipitated for NCL and PTN and analyzed
by Western Blot analysis for the same molecules. B Equal total protein
amounts of subcellular fractions of U87MG cells were
immunoprecipitated for NCL or PTN and analyzed by Western Blot
analysis for PTN or NCL respectively. It should be noted that nuclear NCL
was also detected as a band of lower molecular mass than extranuclear
NCL, in line with the described posttranslational modifications of
extranuclear NCL with complex N- and Oglycosylations (Carpentier et al.,
Biochemistry 2005, 44:5804-5815).
Additional file 4: Exogenous administration of human recombinant
PTN increased the mRNA levels of VEGF190 and VEGF165 and
activated metalloproteinase (MMP)-2 in the chicken embryo CAM.
A. Products of RT-PCR reactions for chicken VEGF190 and VEGF165 and
GAPDH from mRNA of chicken embryo CAM after application of different
doses of PTN. The primers used in the present study amplified both
variants of avian VEGF, as previously described (Giannopoulou et al., J
Pharmacol Exp Ther 2003, 304:729-737). B. Equal amounts of total protein
extracts of chicken embryo CAM from different developmental stages
were analyzed by SDS-PAGE, followed by zymography for MMP-2 and
Western analysis for actin. MMP-2 is the predominant metalloprotease
detected in the CAM (Ribatti et al., J Pharmacol Exp Ther 2003, 304:729-
737; Giannopoulou et al., Int J Cancer 2001, 94:690-698).
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